
- /
- Supported exchanges
- / US
- / CMRX.NASDAQ
Chimerix Inc (CMRX NASDAQ) stock market data APIs
Chimerix Inc Financial Data Overview
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases in the United States. Its product pipeline comprising dordaviprone (ONC201), which is in phase 3 clinical-stage development for H3 K27M-mutant diffuse glioma, as well as in phase 2 Investigator Initiated Clinical Trials for multiple oncology studies; and ONC206, a second generation imipridone ClpP agonist and DRD2 antagonist which is in phase 1 clinical trial to treat central nervous systems and other solid tumors. The company also develops ONC212, an imipridone, investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP, which is in preclinical trial; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of novel coronaviruses. In addition, it offers TEMBEXA, a lipid conjugate which acts via inhibition of viral DNA synthesis that is a medical countermeasure for smallpox. The company has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina. As of April 17, 2025, Chimerix, Inc. operates as a subsidiary of Jazz Pharmaceuticals plc.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Chimerix Inc data using free add-ons & libraries
Get Chimerix Inc Fundamental Data
Chimerix Inc Fundamental data includes:
- Net Revenue: 212 K
- EBITDA: -96 473 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-26
- EPS/Forecast: -0.275
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Chimerix Inc News

Is Chimerix Inc. (CMRX) the Best Performing NASDAQ Stock So Far in 2025?
We recently published a list of 11 Best Performing NASDAQ Stocks So Far in 2025. In this article, we are going to take a look at where Chimerix Inc. (NASDAQ:CMRX) stands against other best performing ...


Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025 Acquisitio...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, BLBX, CMRX, WBA on Behalf of Shareholders
NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or br...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, CMRX, WBA on Behalf of Shareholders
NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or br...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.